Ravanbod Shirin, Faranoush Mohammad, Changi-Ashtiani Majid, Rokni-Zadeh Hassan, Shahani Tina
Molecular Genetics Laboratory, Iranian Hemophilia and Thrombophilia Association (MAHTA), Tehran, Iran.
Pediatric Growth and Development Research Center, Iran University of Medical Sciences, Tehran 1449614535, Iran.
Res Pract Thromb Haemost. 2022 Nov 26;7(1):100003. doi: 10.1016/j.rpth.2022.100003. eCollection 2023 Jan.
As the most frequent congenital rare bleeding disorder that transmits in an autosomal recessive manner, factor VII (FVII) deficiency is a serious bleeding complication in populations with high rate of in-marriages. While diagnosis mainly relies on clinical and laboratory phenotypes, plasma FVII antigen and activity levels do not often correlate with symptoms' severity.
Genetic profiling of the affected individuals potentially improves our biological understanding of this complicated rare disorder.
Conventional polymerase chain reaction-Sanger sequencing and whole-exome sequencing were applied for genetic profiling of gene in 66 symptomatic FVII-deficient individuals from 62 independent pedigrees. Thirty-nine asymptomatic relatives of the patients were also studied.
Thirty different pathogenic variations were identified in the studied cases of which 11 have not been reported before. The novel mutations include 5 missenses (c.715G>A, c.794T>C, c.1090C>G, c.1222C>A, c.1265T>C), 3 splicing (c.316+1G>T, c.682-2A>G, c.572-16C>G), 2 nonsenses (c.790delC, c.1248G>A), and 1 frameshift (c.1346delA). A founder effect is proposed for c.790delC that was detected in 8 independent pedigrees who were all from similar geographical regions and ethnic backgrounds. Homozygous c.790delC reduces plasma FVII activity to <1% and causes spontaneous intracranial hemorrhage in early infancy.
From the 66 studied symptomatic FVII-deficient individuals, 58 were homozygous carriers of the identified variations. Identification of homozygotes clarifies the potential role of nucleotide variations in reducing FVII activity and their contributions to a certain phenotype. Some of those variations, such as c.1A>G, c.509G>A, c.634C>T, and c.1285G>A have only been previously reported as heterozygous.
作为最常见的以常染色体隐性方式遗传的先天性罕见出血性疾病,因子VII(FVII)缺乏症在近亲结婚率高的人群中是一种严重的出血并发症。虽然诊断主要依赖于临床和实验室表型,但血浆FVII抗原和活性水平通常与症状严重程度不相关。
对受影响个体进行基因分析可能会增进我们对这种复杂罕见疾病的生物学理解。
采用常规聚合酶链反应-桑格测序和全外显子组测序对来自62个独立家系的66例有症状的FVII缺乏个体进行基因分析。还研究了39例患者的无症状亲属。
在所研究的病例中鉴定出30种不同的致病变异,其中11种以前未报道过。新突变包括5种错义突变(c.715G>A、c.794T>C、c.1090C>G、c.1222C>A、c.1265T>C)、3种剪接突变(c.316+1G>T、c.682-2A>G、c.572-16C>G)、2种无义突变(c.790delC、c.1248G>A)和1种移码突变(c.1346delA)。对于在8个独立家系中检测到的c.790delC提出了奠基者效应,这些家系均来自相似的地理区域和种族背景。纯合子c.790delC可将血浆FVII活性降低至<1%,并在婴儿早期导致自发性颅内出血。
在66例研究的有症状FVII缺乏个体中,58例为已鉴定变异的纯合携带者。纯合子的鉴定阐明了核苷酸变异在降低FVII活性及其对特定表型的贡献中的潜在作用。其中一些变异,如c.1A>G、c.509G>A、c.634C>T和c.1285G>A以前仅报道为杂合子。